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We designed a hamme~bead ribozyme which site-specifically cleaved the GUC sequence in codon 179 of MBR1 mRNA. The cleavage site was 
6 amino acids upstream from the drug binding site and was considered sufhciently close to the essential locus for P-glycoprotein function. The 
ribozyme cleaved the lMDR1 mRNA under physiological conditions in vitro. The cleavage was dependent on ribozyme concentration and on 
incubation time. Mg2* ion was essential for the cleavage. These results show that a potentially useful tool is at hand which may inactivate MDRl 
mRNA and revert the multidrug resistance phenotype. 
Hammerhead ribozyme; Multidrug resistance 
1” INTRODUCTION 
When tumor cells are exposed to one of many hetero- 
cyclic cytotoxic drugs the cells become resistant o other 
structurally and functionally unrelated drugs [l-3]. This 
phenomenons called MDR, is one of the major obsta- 
cles in cancer chemotherapy. The underlying mecha- 
nism of MDR is the cellular overproduction of P- 
glycoprotein, a 170 kDa transmembrane protein that 
serves as an energy-dependent drug eFRux pump [4]. By 
rapid elimination of drugs that enter the cell, tumor 
resistance can occur despite high blood levels of drugs. 
F-Glycoprotein is encoded by a small group of closely 
related genes termed &fBR; only A3DRl is known to 
confer drug resistance 1%91. Theoretically, P-glycopro- 
tein activity can be blocked at three levels: DNA, RNA 
and protein. Since amplification of the MDRl gene is 
not a prerequisite to P-glycoprotein-related resistance 
in human tumor cells [ 10, 1 11, the potential oci of inhibi- 
tion can be narrowed to the mRNA and protein levels. 
the drug binding site at amino acid codon 185. On the 
premise that the GUC locus was sufficiently close and 
important to the drug binding site, we designed a ham- 
merhead ribozyme of MDRl mRNA for the GUC se- 
quence in codon 179. The ribozyme that we designed 
cleaved MBRI RNA, in trans, at the 
vitro. 
specific site in 
2. MATERIALS AND METHODS 
2.1. Cells and RNA extraction 
The parent MOLT-3 human acute lymphoblastic leukemia cell line 
[14] and drug-resistant sublines were majntain~ in RPM&1640 me- 
dium containing 10% (v/v) FBS and were fed twice a week with fresh 
medium. The rnu~~d~g-~sistant sub&es used were MOLT-U 
VCR ,IKx) (l,O~-fold VCR resistant) [15] and MQLT-3~MQ~ @IO- 
fofd TMQ resistant) [16]. Total ceIIuIar RNA was extracted by acid 
guanidinium thiocyanate-phenol-chloroform method [17]. 
2.2. RT-PCR 
One means to intercept a target mRNA is to use a 
catalytic RNA, or ribozyme [12,X3]. Since ribozymes 
recognize a GUC sequence and cleave it most effi- 
ciently, attempts were made to determine whether a 
GUC sequence is located within any critical region on 
MDRl mRNA. We observed that one GUC sequence 
is located at codon 179, 6 amino acids upstream from 
For the RT-PCR of lMDR1 transcripts, cDNA was synthesized by 
using Moloney murine leukemia virus reverse transcriptase (G&co. 
Grand Wand, NY) with random hexamer (Pharmacia, Piscataway, 
NJ) as a primer. Exons 6 througfi 8 were then amplified from this 
FDNA by using GeneAmp PCR Core Reagent Kit (Perkin-Elmer 
Cetus, Norwalk, CT) with oligonucleotide primers from exon 6 (S- 
TTCATGCTATAATGCGACAGGAGATA) and exon 8 (S- 
TTCT’ITATCAGTAAATGAAGATAGTA). The clear and distinct 
266-bp product was identified in 1.8% agarose gel and X x Tris-acetate 
EDTA buffer. 
Cu~~e~~~~~~~~ addrew: T. Ohnuma, Department of Neopiastic Dis- 
eases, Box IX& Mount Sinai Medical Center, One Gustave L. Levy 
Place, New York, NY 10029, USA. Fax: (I) (212) 860-7186. 
2.3. C&ring of PCR products and ~~~~~~ 
The PCR products were ligated dire&y to pT7BIue T-vector (No- 
Abbreviutmzx MDR, multidrug resistance; FBS, fetal bovine serum; 
VCR, vincristine: TMQ, trimetrexate; RT-PCR, reverse transcription 
polymerase chain reaction; CTAB, cetyl-trimethylammonium bro- 
mide. 
vagen, Madison, WI). After transformation of E. eoh, colonies were 
selected and screened. Plasmid DNA was prepared by CTAB-DNA 
precipitation method and double-stranded DNA sequencing was per- 
formed directly after alkali denaturation by using Sequenase version 
2.0 kit (U.S. Biochemical, Cleveland, OH) [18]. At least 6 clones of 
each subline were sequenced and analyzed for the orientation. The 
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Fig. 1. Structure of the MDRl ribozyme and the complementary 
MDRl RNA with the GUC cleavage site. 
clones that could produce the sense transcript were chosen for making 
MDRl RNA substrate as described below. 
2.4. In vitro transcription of RNA (MDRI or ribozvme) from plasmtd 
templates or synthetic DNA template 
Transcriptions of RNAs from plasmid templates that contained T7 
RNA polymerase promoter were carried out by using Riboprobe 
Gemini II Core System (Promega, Madison, WI). The transcription 
reaction mixture contained 5 mg linearized plasmid DNA cut with 
BarnHI, 0.5 U/,ul T7 RNA polymerase, 40 mM Tris-HCI, pH 7.5, 6 
mM MgCI?, 10 mM NaCl. 2 mM spermidine, 10 mM dithiothreitol, 
0.5 mM ATP, GTP and UTP, 0.1 mM CTP, 100 mCi of [a-‘*P]CTP 
(specific activity 800 Ci/mmol) (DuPont, Boston, MA); and 1 U/ml 
recombinant ribonuclease inhibitor m a 100 ~1 volume. The reactions 
were carried out at 30°C for 3 h. The products were treated with RQl 
RNAse-free DNAse (Promega) followed by phenol-chloroform ex- 
traction and ammonium acetate thanol precipitation. 
To synthesize the A4DRl ribozyme a set of primers was used. One 
primer contained the bacteriophage T7 RNA polymerase promoter 
sequence (S-ATTAATACGACTCACTATAGAATCTTGGACTG- 
ATGAG) and the other primer was S’-AGATGATGTTTCGTCCT- 
CACGGACTCATCAGTC. The primers were mixed to form a hem- 
tduplex, and PCR amplification was performed. The transcrrption of 
RNA from the synthetic DNA template was carried out under similar 
conditions except we used the same amount of cold rNTP’s without 
[cr-“P]CTP. The synthetic DNA template concentration in the reac- 
tion mixture was 0.02 mg/ml. 
2.5. In wtro cleavage reactions 
The ribozyme and substrate RNA were mixed in a 10 ~1 reaction 
volume containing 50 mM Tris-HCI, pH 7.5, and 1 mM EDTA. The 
mixture was heated to 95°C for 2 min, quick-cooled on ice, various 
concentrations of MgCI, were added, and then it was incubated at 
37°C for various amounts of time. The reactions were stopped by the 
addition of an equal volume of stop solution (95% formamide, 20 mM 
EDTA, 0.05% Bromophenol blue, 0.05% xylene cyanol), heated at 
65°C for 5 min, analyzed in a 6% polyacrylamide-7 M urea gel in 
Tris-borate EDTA buffer and autoradiographed. 
3. RESULTS AND DISCUSSSION 
In the present study, a hammerhead ribozyme was 
designed to cleave the GUC sequence of the codon 179 
in exon 7 of the MDRl gene in MOLT-3 human acute 
lymphoblastic leukemia cells resistant o TMQ or VCR 
(Fig. 1). This site is only 6 amino acids away from the 
drug binding site that is considered an essential locus for 
P-glycoprotein function. We reasoned that, if we specif- 
ically cleaved the mRNA at a crucial site, the resulting 
mRNA fragments would be non-functional, even if the 
fragments happened to be translated into polypeptides. 
The hammerhead ribozyme we designed was based on 
the trans-acting ribozyme described by Haseloff and 
Gerlach [13]. It had the same ribozyme’s core sequence 
as theirs and flanking sequences totalling 18 nucleo- 
tides, 9 on both ends of the catalytic center. These 18 
nucleotides formed base pairs specifically with the 
MDRl substrate. 
We have previously shown that both MOLT-31 
TMQBoo and MOLT-3/VCR,.m,, display MDRl mRNA 
overexpression and P-glycoprotein overproduction 
[15]. In this study we confirmed this in that the 266-bp 
PCR products of MDRl could be amplified only from 
the resistant cells but not from the parent cell line (data 
not shown). The primers used are specific only for 
MDRl, not for MDR2, which does not confer MDR 
phenotype. Furthermore, sequencing the RT-PCR 
products of MOLT-3/TMQs,0 and MOLT-3NCR,,00, 
showed that there were no mutations between codon 
156 and 243 of MDRl (Fig. 2), indicating that the ri- 
bozyme designed could work efficiently. 
Transcription from the plasmid template that con- 
tained the MDRl RT-PCR product using T7 RNA 
polymerase and [a-32P]CTP generated a radioactive 
329-base MDRl RNA substrate. This substrate and the 
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Frg. 2. cDNA sequence analysis of the MDRl gene of MOLT-31 
TMQ,, cells in the target region of the MDRl ribozyme. The sequenc- 
ing template used was double-stranded pT7Blue T-vector plasmid 
DNA containing the RT-PCR product of the MDRI mRNA (codon 
156243). Dideoxy sequencing was performed. 
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Fig, 3. Cleavage of MDRl substrate (329 bases) by the MDRl ribozyme to two cleavage products. 5’ fragment (5’F) is 128 bases long and contains 
the 5’ portion of the MDRl substrate and plasmid sequence. 3’ fragment (‘F) is 201 bases long and contains the 3’ portion of the MI)Rl substrate. 
only the substrate was labeled with [a-‘*P]CTP. (A) Cleavage reaction with increasing proportions of the ribozyme. Ri~~e/RNA ratio is shown 
on a molar basis. The reaction was run for 12 h in physiological pH and temperature in the presence of 10 mM MgCl,. (B) Reaction time vs. activity 
profiles of the ribozyme. Equimolar amounts of ribozyme and substrate were incubated in the presence of 10 mM MgCl,. (C) Optimization of MgCI, 
concentration for the cleavage reactron. Equimolar amounts of ribozyme and substrate were incubated with various concentrations of MgClr for 
12 h. 
ribozyme were used to determine the specificity of ri- 
bozyme cleavage and to optimize cleavage conditions in 
vitro. Incubation of the ML?RI RNA substrate with the 
MDR ribozyme at physiological pH and temperature 
resulted in specific cleavage of the substrate to 201 and 
128 base products (Fig. 3A). Increases in the amounts 
of the ribozyme relative to substrate resulted in progres- 
sively large amounts of cleavage products. The cleavage 
reaction was also time dependent. Thus, substantial 
cleavage occurred within 1 h and progressed continually 
over 12 h of incubation period (Fig. 3B). The cleavage 
reaction also had an absolute requirement for Mg” 
(Fig. 3C). 
Chang et al. designed the same type of hammerhead 
ribozyme against HIV-l gag gene which had 16 base 
flanking sequences [19]. Under the same conditions we 
used, they observed substantial cleavage of the 13% 
nucleotide long gag substrate after 30 min and complete 
cleavage in 14 h. The cleavage reaction we observed 
may be somewhat slower than theirs. This may be due 
to 2 extra nucleotides in the flanking sequences of our 
ribozyme as compared to theirs. Goodchild and Kohli 
[20] examined the effects of the length of base-paired 
flanking sequences on ribozyme kinetics. They observed 
that reduction of the length of flanking sequences from 
20 to 12 base pairs resulted in lo-fold increases in the 
rate of cleavage reaction. 
Ribozymes have been proposed as anti-HIV agents 
[21] as well as agents to cleave mutated ras oncogene 
1221. The availability of a ribozyme active against 
A4t)Rl mRNA offers hope that the MDR phenotype 
may be reverted by this agent. We have begun work 
towards this goal. 
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